Mereo BioPharma Group plc MREO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -50.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -50.00% | -- |
| Cost of Revenue | -100.00% | -- | -- | 148.35% | -- |
| Gross Profit | -100.00% | -- | -- | -71.09% | -- |
| SG&A Expenses | -23.36% | -28.93% | -12.95% | 7.17% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.71% | -23.03% | -15.22% | 17.34% | -- |
| Operating Income | 25.88% | 24.09% | 16.31% | -19.11% | -- |
| Income Before Tax | 43.29% | 24.33% | 3.18% | 9.32% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.29% | 24.33% | 3.18% | 8.26% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.29% | 24.33% | 3.18% | 8.26% | -- |
| EBIT | 25.88% | 24.09% | 16.31% | -19.11% | -- |
| EBITDA | 26.79% | 24.97% | 17.05% | -19.63% | -- |
| EPS Basic | 44.61% | 28.31% | 10.07% | 15.84% | -- |
| Normalized Basic EPS | 44.61% | 28.29% | 10.11% | 16.94% | -- |
| EPS Diluted | 44.61% | 28.31% | 10.07% | 15.84% | -- |
| Normalized Diluted EPS | 44.61% | 28.29% | 10.11% | 16.94% | -- |
| Average Basic Shares Outstanding | 2.45% | 5.27% | 7.67% | 9.60% | -- |
| Average Diluted Shares Outstanding | 2.45% | 5.27% | 7.67% | 9.60% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |